Pancreatic cancer
- PMID: 12057145
- DOI: 10.1007/s11864-000-0065-2
Pancreatic cancer
Abstract
Optimal therapy for pancreatic adenocarcinoma requires surgical removal with tumor-free margins. Superior outcomes have been reported for high-volume centers incorporating a multidisciplinary approach. Postoperative ("adjuvant") chemotherapy and radiation should be considered in patients with successfully resected primary tumors. Combined modality treatment with chemotherapy and radiation should be considered for locally advanced, unresectable tumors. Gemcitabine can provide symptom relief and a modest improvement in survival for patients with metastatic disease. Strict attention to relief of symptoms such as pain, depression, anorexia/cachexia, and jaundice is essential in all patients with pancreatic cancer. All patients with pancreatic cancer should be encouraged to enter clinical trials of new therapies, given that long-term survival for all stages remains poor.
Similar articles
-
Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.Clin J Oncol Nurs. 2008 Aug;12(4):599-605. doi: 10.1188/08.CJON.599-605. Clin J Oncol Nurs. 2008. PMID: 18676327 Review.
-
Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.Ann Surg. 2009 Jul;250(1):88-95. doi: 10.1097/SLA.0b013e3181ad65cc. Ann Surg. 2009. PMID: 19561477
-
Resection and radiochemotherapy of pancreatic cancer--the future?Langenbecks Arch Surg. 1998 Apr;383(2):134-44. doi: 10.1007/pl00008075. Langenbecks Arch Surg. 1998. PMID: 9641886 Review.
-
Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.Hematol Oncol Clin North Am. 2002 Feb;16(1):53-79. doi: 10.1016/s0889-8588(01)00010-7. Hematol Oncol Clin North Am. 2002. PMID: 12063829 Review.
-
[Role of adjuvant chemoradiotherapy in the therapeutic strategy of exocrine adenocarcinoma of the pancreas].Cancer Radiother. 1997;1(5):542-6. doi: 10.1016/s1278-3218(97)89636-9. Cancer Radiother. 1997. PMID: 9587387 Review. French.
Cited by
-
Feasibility and yield of a novel 22-gauge histology EUS needle in patients with pancreatic masses: a multicenter prospective cohort study.Surg Endosc. 2013 Oct;27(10):3733-8. doi: 10.1007/s00464-013-2957-9. Epub 2013 May 4. Surg Endosc. 2013. PMID: 23644834 Clinical Trial.
-
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e475-81. doi: 10.1016/j.ijrobp.2012.06.003. Epub 2012 Jul 17. Int J Radiat Oncol Biol Phys. 2012. PMID: 22818416 Free PMC article. Clinical Trial.
-
Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma.Ann Hepatobiliary Pancreat Surg. 2018 Aug;22(3):197-207. doi: 10.14701/ahbps.2018.22.3.197. Epub 2018 Aug 31. Ann Hepatobiliary Pancreat Surg. 2018. PMID: 30215041 Free PMC article.
-
An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO.BMC Cancer. 2009 Nov 27;9:412. doi: 10.1186/1471-2407-9-412. BMC Cancer. 2009. PMID: 19943918 Free PMC article. Clinical Trial.
-
Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction.Tumour Biol. 2014 Oct;35(10):10185-93. doi: 10.1007/s13277-014-2315-0. Epub 2014 Jul 16. Tumour Biol. 2014. PMID: 25027401
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical